GlassScriptPhysician profile
Davida D Prater
NPI 1447287230
$45,888.13
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,581 · 2022: $17K · 2023: $16K · 2024: $5,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $4,197 · Food and Beverage: $2,512 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,805.00 |
| Travel and Lodging | $4,196.91 |
| Food and Beverage | $2,512.33 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25,560.02 | 2021-2024 | Epclusa |
| Abbvie INC. | $19,423.17 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.13 | 2023-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $200.95 | 2022-2024 | Stelara, Simponi Aria, Tremfya |
| Genzyme Corporation | $83.93 | 2022-2024 | |
| Qol Medical, LLC | $55.12 | 2024 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $47.00 | 2024 | Eohilia, Entyvio |
| Regeneron Healthcare Solutions, INC. | $46.71 | 2023-2024 | Dupixent |
| Celgene Corporation | $35.09 | 2023-2024 | Zeposia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.13 | 2023 | Jublia, Duobrii, Arazlo |
| Braintree Laboratories, INC. | $24.87 | 2022 | |
| Pfizer INC. | $23.22 | 2024 | |
| Amgen INC. | $21.88 | 2023 | Amjevita, Avsola |
| Lilly USA, LLC | $21.40 | 2023 | |
| Alnylam Pharmaceuticals INC. | $18.35 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $17.37 | 2023 | |
| Fresenius Kabi USA, LLC | $16.08 | 2024 | Idacio |
| Ironwood Pharmaceuticals, INC | $15.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davida Prater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.